Abstract
Cardiometabolic disorders (CD), including cardiovascular disease (CVD), diabetes, and obesity, are the leading cause of health concern in the United States (U.S.), disproportionately affecting indigenous populations such a Native Hawaiian and Other Pacific Islanders (NHOPI). Dyslipidemia, a prevalent risk factor for the development and progression of CVD, is more prone to occur in NHOPI than other populations in the U.S. High-intensity statin therapy to reduce low-density lipoprotein cholesterol is associated with the prevention of CVD events. However, significant side-effects, such as muscle disorders, have been associated with its use. Different ethnic groups could experience variation in the prevalence of statin side effects due to sociodemographic, behavioral, and/or biological factors. Therefore, identifying the most impactful determinants that can be modified to prevent or reduce statin side effects for individuals from high-risk ethnic minority groups, such as NHOPI, can lead to more effective strategies to reduce health disparities. Thus, our Mini-Review explores the challenging aspects of public health precise strategies in NHOPI taking statins, including a culturally informed additional therapy that could positively impact the NHOPI population.
Highlights
The burden of cardiovascular diseases (CVD) and its associated risk factors, such as dyslipidemia, obesity, and diabetes mellitus, are not distributed across racial and ethnic groups [1]
Identifying the most impactful determinants that can be modified to prevent or reduce statin side effects in the Native Hawaiians and Other Pacific Islanders (NHOPI) population is essential to developing interventions that best meet the needs of this population [7]
Sun et al [11], studying traits for which the Native Hawaiians exhibit excess risk, observed that 2,239 individuals (56.8%) presented hyperlipidemia, in which 657 individuals were undiagnosed. This result corroborates previous findings in which high cholesterol levels were reported by 59% of NHOPI participants, with a higher prevalence among males (66%) compared to females (49%) [15]. These findings suggest that a significant part of the NHOPI population may be eligible for statin therapy
Summary
The burden of cardiovascular diseases (CVD) and its associated risk factors, such as dyslipidemia, obesity, and diabetes mellitus, are not distributed across racial and ethnic groups [1]. Data from the National Health Interview Survey shows that Native Hawaiians and Other Pacific Islanders (NHOPI) have a greater prevalence of heart disease relative to non-Hispanic Whites, non-Hispanic Blacks, and Asians [1] Several factors, such as sociodemographic, behavioral, and biological, alone or in combination, may create disparities in health within this population [1, 2]. Sun et al [11], studying traits for which the Native Hawaiians exhibit excess risk, observed that 2,239 individuals (56.8%) presented hyperlipidemia (or dyslipidemia), in which 657 individuals were undiagnosed This result corroborates previous findings in which high cholesterol levels were reported by 59% of NHOPI participants, with a higher prevalence among males (66%) compared to females (49%) [15]. It remains to be investigated if NHOPI may present a particular genetic polymorphism that may enhance or protect against statin-associated muscle symptoms in this population
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
